KR20050096147A - 비뇨기 장애 치료용 톨테로딘 및 다른 항무스카린제의감소량 투여 - Google Patents

비뇨기 장애 치료용 톨테로딘 및 다른 항무스카린제의감소량 투여 Download PDF

Info

Publication number
KR20050096147A
KR20050096147A KR1020057013495A KR20057013495A KR20050096147A KR 20050096147 A KR20050096147 A KR 20050096147A KR 1020057013495 A KR1020057013495 A KR 1020057013495A KR 20057013495 A KR20057013495 A KR 20057013495A KR 20050096147 A KR20050096147 A KR 20050096147A
Authority
KR
South Korea
Prior art keywords
tolterodine
urinary
pharmaceutically effective
use according
effective dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057013495A
Other languages
English (en)
Korean (ko)
Inventor
바바라 에이치. 코벌리
수잔 엠. 데인하워
Original Assignee
피저 헬스 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32771960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20050096147(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 피저 헬스 에이비 filed Critical 피저 헬스 에이비
Publication of KR20050096147A publication Critical patent/KR20050096147A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020057013495A 2003-01-22 2004-01-14 비뇨기 장애 치료용 톨테로딘 및 다른 항무스카린제의감소량 투여 Ceased KR20050096147A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44169003P 2003-01-22 2003-01-22
US60/441,690 2003-01-22

Publications (1)

Publication Number Publication Date
KR20050096147A true KR20050096147A (ko) 2005-10-05

Family

ID=32771960

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057013495A Ceased KR20050096147A (ko) 2003-01-22 2004-01-14 비뇨기 장애 치료용 톨테로딘 및 다른 항무스카린제의감소량 투여

Country Status (17)

Country Link
US (2) US20060047007A1 (https=)
EP (1) EP1589958B2 (https=)
JP (1) JP2006515607A (https=)
KR (1) KR20050096147A (https=)
CN (1) CN1741796A (https=)
AT (1) ATE432070T1 (https=)
AU (1) AU2004206110A1 (https=)
BR (1) BRPI0406861A (https=)
CA (1) CA2514022C (https=)
DE (1) DE602004021233D1 (https=)
ES (1) ES2324712T5 (https=)
IL (1) IL169362A0 (https=)
MX (1) MXPA05007767A (https=)
PL (1) PL377995A1 (https=)
TW (1) TW200418447A (https=)
WO (1) WO2004064821A1 (https=)
ZA (1) ZA200505026B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
DK2210605T3 (en) * 2003-11-04 2017-05-22 Tcd Royalty Sub Llc Daily single dose doses of trospium.
ES2322148T3 (es) * 2004-08-11 2009-06-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias.
PT1986642E (pt) * 2006-02-13 2014-01-30 Orient Pharma Samoa Co Ltd Combinação de agonista do receptor alfa-2 (clonidina) e um agente antimuscarínico (oxibutinina) para o tratamento de sialorreia
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
WO2011109403A1 (en) * 2010-03-01 2011-09-09 Xenoport, Inc. Use of (3r)-4-{[(1s)-2-methyl-1- (2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
JP2000515525A (ja) 1996-07-19 2000-11-21 アベーグ，グンナー 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン
SK287111B6 (sk) * 1998-08-27 2009-12-07 Pharmacia & Upjohn Ab Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
NZ518309A (en) * 1999-11-11 2003-05-30 Pharmacia Ab Controlled release tolterodine formulation that releases not less than 80% of the active compound in under 18 hours

Also Published As

Publication number Publication date
ES2324712T5 (es) 2012-06-08
TW200418447A (en) 2004-10-01
BRPI0406861A (pt) 2006-01-03
DE602004021233D1 (de) 2009-07-09
ES2324712T3 (es) 2009-08-13
JP2006515607A (ja) 2006-06-01
CN1741796A (zh) 2006-03-01
EP1589958B1 (en) 2009-05-27
WO2004064821A1 (en) 2004-08-05
ZA200505026B (en) 2006-07-26
CA2514022C (en) 2010-07-13
ATE432070T1 (de) 2009-06-15
CA2514022A1 (en) 2004-08-05
PL377995A1 (pl) 2006-02-20
US20060047007A1 (en) 2006-03-02
US20070155838A1 (en) 2007-07-05
MXPA05007767A (es) 2006-01-31
AU2004206110A1 (en) 2004-08-05
EP1589958A1 (en) 2005-11-02
EP1589958B2 (en) 2012-04-11
IL169362A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
EP1039882B1 (en) Therapeutic formulation for administering tolterodine with controlled release
JP6226916B2 (ja) 医薬組成物
RU2435610C2 (ru) Терапия для лечения заболевания
JP5933176B2 (ja) タペンタドールの用量調節
JP2006520799A (ja) 平滑筋調節因子およびα２δサブユニットカルシウムチャネル調節因子を用いた、下部尿路障害を処置するための方法
KR20060109493A (ko) 비만을 치료하기 위한 조합 약물 치료
MX2012011395A (es) Metodos de mejoramiento de la calidad del sueño.
Lose et al. Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor.
US6086914A (en) Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
US20070155838A1 (en) New Method for Treating Urinary Disorders
US10500170B2 (en) Composition and method for treating neurological disease
EP1223914B1 (en) Orally distintegrating composition comprising mirtazapine
HRP20031057A2 (en) Tablet comprising cetirizine and pseudoephedrine
KR102927058B1 (ko) 진통 가려움 완화 약학 조성물 및 그 응용 방법
US8901177B2 (en) Method of treating bladder disorders
AU2015305430A1 (en) Method for treating hyperhidrosis
HK1084028A (en) Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
US20240226024A1 (en) Synergistic effects on weight loss, improved quality of life and reduced gastro-intestinal side effects with a composition of orlistat and acarbose
Aharony et al. Systemic and intrathecal pharmacologic treatment
Lai et al. Pharmacologic treatment for detrusor overactivity
Majmudar et al. Current drug treatments for female urinary incontinence
Biller et al. Overactive bladder: Pharmacologic therapy
Cohen Current medical therapy
JPH09136843A (ja) 血圧上昇薬
MXPA00005215A (en) Therapeutic formulation for administering tolterodine with controlled release

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050721

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20050725

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060825

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20070214

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20060825

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20070516

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20070214

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20080130

Appeal identifier: 2007101005177

Request date: 20070516

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20070615

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20070516

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20061127

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20050725

Patent event code: PB09011R02I

E801 Decision on dismissal of amendment
PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20070709

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20070615

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20061127

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20050725

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20070516

Effective date: 20080130

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20080130

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20070516

Decision date: 20080130

Appeal identifier: 2007101005177